No Data
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination With FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
Alta Copper Announces Non-Brokered Financing With Fortescue Ltd.
Express News | Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
No Data
No Data
